Infants, children 3 months and older: IV 60-100 mg/kg/DAY divided q6h.MAX daily dose 4 g.
Infants less than 3 months: IV: 100 mg/kg/DAY divided q6h
Dosage recommendations are based on imipenem component.
Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing. Patient weight less than 30 kg and impaired renal function, use not recommended.
multidrug-resistant gram-negative infection of the lower respiratory tract, urinary tract, intra-abdominal, gynecologic, bone and joint, septicemias, endocarditis, and skin; treatment of multiple organism infection in which other agents have an insufficient spectrum of activity or are contraindicated due to toxic potential; therapeutic alternative for treatment of gram-negative sepsis in immunocompromised patients. Has also been used for the treatment of peritonitis in patients with peritoneal catheters
Renal and hepatic function, CBC.
phlebitis, tachycardia, seizure, rash, GI upset, decrease blood counts, hepatic dysfunction, acute renal failure, cytopenias, bone marrow suppression
May alter cyclosporine levels, cyclosporine may enhance neurotoxic effect. Ganciclovir/Valganciclovir may increase seizure risk. Valproic acid - carbapenems decrease valproate levels and may decrease seizure threshold.
Antimicrobial class: carbapenem
Average serum half life:
Prolonged with renal insufficiency (both drugs) Neonates:
Imipenem: 1.7-2.4 hours.<br>Cilastatin: 3.9-6.3 hours.
Infants and children: Imipenem: 1.2 hours
Adults, both drugs: 1 hour
Route of Elimination: When imipenem is given with cilastatin, urinary excretion of unchanged imipenem increases to 70%; 70% to 80% of a cilastatin dose is excreted unchanged in the urine